BeStock  
Stocks › Biotechnology › PHVS

Pharvaris PHVS

US equityMarket cap rank #2618Biotechnology
$31.28 −$0.38 (-1.20%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $31.28 0.00%
Open$31.41
Prev close$31.66
Day range$30.43 – $31.99
Volume464.0K
Market cap$2.21B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026 · reported in EUR

Revenue€0.00
Operating profit-€50.08M-26.3% YoY
Net profit-€47.41M-27.7% YoY
Diluted EPS-€0.67-11.7% YoY
Free cash flow-€42.22M-37.6% YoY
Operating cash flow-€42.22M

Revenue, last 8 quarters

€0.0Dec '24€0.0Mar '25€0.0Jun '25€0.0Sep '25€0.0Dec '25€0.0Mar '26€0.0Jun '26€0.0Sep '26

Net profit, last 8 quarters

€-34.8MDec '24€-46.3MMar '25€-45.5MJun '25€-37.1MSep '25€-46.7MDec '25€-39.2MMar '26€-47.8MJun '26€-47.4MSep '26

Diluted EPS by quarter

-0.64Dec '24-0.85Mar '25-0.83Jun '25-0.60Sep '25-0.71Dec '25-0.60Mar '26-0.70Jun '26-0.67Sep '26

Free cash flow by quarter

€-35.1MDec '24€-38.6MMar '25€-30.0MJun '25€-30.7MSep '25€-38.0MDec '25€-48.8MMar '26€-37.8MJun '26€-42.2MSep '26

Annual revenue

€0.0FY20€0.0FY21€0.0FY22€0.0FY23€0.0FY24€0.0FY25

Profitability & balance sheet

Return on equity-62.8%
Return on assets-57.2%
Return on invested capital-62.7%
Current ratio9.89
Liabilities / assets10.2%
Cash & investments€282.73M
Total debt€430,277.00
Net cash (debt)€282.30M

This company reports in its own local currency, not U.S. dollars. Every figure below is labeled with its real currency, not automatically converted.

Income statement

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Total Operating Revenue €0.00 €0.00 €0.00 €0.00 €0.00
Operating Expense €50.08M €50.79M €44.27M €169.82M €47.60M
Selling and Admin Expenses €17.66M €15.79M €14.11M €45.34M €13.46M
-General & Admin Expense €17.66M €15.79M €14.11M €45.34M €13.46M
Research & Development €32.42M €35.00M €30.16M €124.48M €34.14M
Operating Profit -€50.08M -€50.79M -€44.27M -€169.82M -€47.60M
Net Non-Operating Interest Income (Expense) €1.91M €1.91M €5.34M €6.36M €2.13M
Non-Operating Interest Income €2.00M €1.98M – – –
Total Other Finance Costs €93,498.00 €72,599.00 -€5.34M -€6.36M -€6.48M
Other Income (Expense) €974,898.00 €1.64M – -€10.25M €394,364.00
Gain on Sale of Security €974,898.00 €1.64M – -€10.25M €394,364.00
Pretax Profit -€47.20M -€47.24M -€38.93M -€173.71M -€45.08M
Tax €214,524.00 €602,200.00 €273,107.00 €1.99M €1.66M
Net Profit -€47.41M -€47.84M -€39.20M -€175.70M -€46.74M
Profit from Continuing Operations -€47.41M -€47.84M -€39.20M -€175.70M -€46.74M
Net Income to Parent Company -€47.41M -€47.84M -€39.20M -€175.70M -€46.74M
Net Income to Common Stockholders -€47.41M -€47.84M -€39.20M -€175.70M -€46.74M
Basic EPS -€0.67 -€0.70 -€0.60 -€2.97 -€0.71
Diluted EPS -€0.67 -€0.70 -€0.60 -€2.97 -€0.71

Balance sheet

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Total Assets €295.06M €328.67M €259.79M €301.45M €301.45M
Total Current Assets €293.21M €326.88M €257.68M €299.17M €299.17M
Cash and Cash Equivalents & Short-Term Investments €282.73M €318.28M €246.96M €291.68M €291.68M
-Cash and Cash Equivalents €282.73M €318.28M €246.96M €291.68M €291.68M
Receivables €5.98M €5.27M €4.98M €4.55M €4.55M
-Taxes Receivable €5.98M €5.27M €4.98M €4.55M €4.55M
Prepaid Assets €4.49M €3.33M €5.75M €2.94M €2.94M
Total Non-Current Assets €1.86M €1.79M €2.10M €2.29M €2.29M
Net PPE €1.11M €1.21M €1.36M €1.40M €1.40M
-Gross PPE €1.72M €1.80M €1.82M €1.81M €1.81M
-Accumulated Depreciation -€612,328.00 -€584,985.00 -€460,654.00 -€409,286.00 -€409,286.00
Non-Current Deferred Assets €746,063.00 €579,111.00 €747,532.00 €887,352.00 €887,352.00
Total Liabilities €30.09M €27.86M €23.46M €30.18M €30.18M
Total Current Liabilities €29.66M €27.38M €22.92M €29.60M €29.60M
Payables €5.30M €2.79M €3.67M €6.06M €6.06M
-Accounts Payable €5.30M €2.79M €2.71M €5.11M €5.11M
-Total Tax Payable €0.00 €0.00 €960,809.00 €941,209.00 €941,209.00
Current Accrued Expenses €13.99M €16.45M €12.08M €11.92M €11.92M
Short-Term Debt and Capital Lease Obligation €173,658.00 €192,395.00 €206,311.00 €200,213.00 €200,213.00
-Current Capital Lease Obligation €173,658.00 €192,395.00 €206,311.00 €200,213.00 €200,213.00
Total Non-Current Liabilities €430,277.00 €481,333.00 €532,580.00 €576,585.00 €576,585.00
Long Term Debt and Capital Lease Obligation €430,277.00 €481,333.00 €532,580.00 €576,585.00 €576,585.00
-Long Term Capital Lease Obligation €430,277.00 €481,333.00 €532,580.00 €576,585.00 €576,585.00
Total Equity €264.97M €300.81M €236.33M €271.27M €271.27M
Stockholders' Equity €264.97M €300.81M €236.33M €271.27M €271.27M
Capital Stock €8.50M €8.42M €7.85M €7.83M €7.83M
-Common Stock €8.50M €8.42M €7.85M €7.83M €7.83M
Additional Paid-In Capital €916.07M €905.06M €795.29M €792.55M €792.55M
Retained Earnings -€716.58M -€668.58M -€619.54M -€579.60M -€579.60M
Gains/Losses Not Affecting Retained Earnings €56.99M €55.90M €52.73M €50.50M €50.50M

Cash flow

Line item 2026 Q3
(EUR)
2026 Q2
(EUR)
2026 Q1
(EUR)
2025 ANNUAL
(EUR)
2025 Q4
(EUR)
Operating Cash Flow -€42.22M -€37.80M -€48.77M -€137.07M -€37.95M
Net cash flow from continuing operations -€42.22M -€37.80M -€48.77M -€137.07M -€37.95M
Net Income from Continuing Operations -€47.20M -€47.24M -€38.93M -€173.71M -€45.08M
Gain/Loss from Continuing Operations -€2.17M -€2.54M -€4.11M €11.74M -€239,583.00
Depreciation & Depletion & Amortization €92,390.00 €179,299.00 €104,726.00 €418,353.00 €104,868.00
Other Non-Cash Items €87,450.00 €73,189.00 €75,826.00 -€439,591.00 -€29,121.00
Change in Working Capital €1.02M €6.73M -€10.61M €7.62M €4.87M
-Change in Receivables -€457,186.00 -€70,704.00 -€286,166.00 -€331,339.00 -€389,161.00
-Change in Payables and Accrued Expense €4.74M €4.09M -€9.10M €6.21M €5.06M
-Change in Other Current Assets -€3.26M €2.71M -€1.23M €1.75M €201,598.00
Net cash flow from investing €0.00 -€26,907.00 -€52,097.00 -€164,619.00 -€1,538.00
Net Cash Flow from Continuing Investing Activities €0.00 -€26,907.00 -€52,097.00 -€164,619.00 -€1,538.00
Net PPE Purchase and Sale €0.00 -€26,907.00 -€52,097.00 -€164,619.00 -€1,538.00
Financing Cash Flow €6.13M €105.87M -€61,514.00 €160.61M €271,491.00
Net Cash Flow from Continuing Financing Activities €6.13M €105.87M -€61,514.00 €160.61M €271,491.00
Net Issuance Payments Of Debt -€62,435.00 -€62,038.00 -€61,514.00 -€219,013.00 -€66,316.00
Net Common Stock Issuance €6.22M €113.13M €0.00 €171.74M €337,338.00
Net Other Financing Charges -€29,420.00 – – -€10.91M €469.00
Ending Cash Balance €282.73M €318.28M €246.96M €291.68M €291.68M
Net Change in Cash -€36.09M €68.05M -€48.88M €23.37M -€37.68M
Beginning Cash Balance €318.28M €246.96M €291.68M €280.73M €329.29M
Effect of Exchange Rate Changes €537,548.00 €3.28M €4.16M -€12.42M €76,064.00
Free Cash Flow -€42.22M -€37.83M -€48.82M -€137.24M -€37.95M

Discussion

No comments yet — be the first to weigh in on PHVS.

Sign in to join the discussion.

Scroll to Top